anti-parkinsonian

Atipamezole is a synthetic α2 adrenergic receptor antagonist. It has also been researched in humans as a potential anti-Parkinsonian drug. Atipamezole hydrochloride (MPV-1248 hydrochloride) is hydrochloride form of atipamezole.

Omarigliptin is a potent and selective oral dipeptidyl peptidase 4 (DPP4) inhibitor with IC50 value of 1.6 nM. [3]

Amantadine is used both as an antiviral and an anti-parkinsonian drug. Amantadine is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release, and blocks dopamine reuptake. The drug has many effects in the brain, including the rel

Rotigotine Hydrochloride (N-0924), a dopamine receptor agonist prefering for D3 receptors over D1 and D2, has effective activity of anti-Parkinsonian. Racemic rotigotine hydrochloride is about 50 times as potent as quinpirole, the gold standard D2 agonist.

Atipamezole (Antisedan) is a synthetic α2 adrenergic receptor antagonist. It has also been researched in humans as a potential anti-Parkinsonian drug.

D-685, a prodrug of D-520, demonstrates enhanced anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model compared to its parent compound D-520. It effectively reduces the buildup of human α-synuclein (α-syn) protein and readily penetrates the brain [1].

Gynosaponin TN-2, demonstrating anti-Parkinsonian activity, mitigates L-DOPA (100 and 200 μM)-induced apoptotic cell death in pheochromocytoma 12 cells through the modulation of extracellular signal-regulated protein kinases 1 and 2 activation.